Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05487885

Organisation Name: University of Pittsburgh

Overal Status: Recruiting

Start Date: July 22, 2022

Last Update: August 4, 2022

Lead Sponsor: Erika Forbes

Brief Summary: The goal of the ADEPT Study is to understand anhedonia in young people and how it changes based on treatments targeting the brain circuit underlying it. Anhedonia is a challenging mental health symptom that involves difficulty with motivation to experience pleasant events. This study could help develop treatments for people whose depression does not improve with traditional treatments.

The ADEPT Study includes two phases. In Phase 1, participants are asked to go through a series of activities to measure anhedonia, including MRI scans, blood draws, behavioral tasks, clinical interviews, questionnaires, and app-based assessments of experiences and behaviors. Phase 2 involves therapeutic activities, such as transcranial magnetic stimulation (TMS), positive affect training, and, for some people, ketamine administration. If the participant qualifies and is interested, they may choose to do Phase 2 activities in addition to Phase 1.

Conditions:
  • Depression
  • Anhedonia


Total execution time in seconds: 0.32827305793762